Drug Profile
PRG 1801
Alternative Names: BCMA CAR-T cell therapy - Pregene Shenzhen Biotechnology; BCMA nano-antibody CAR-T cell therapy - Pregene Shenzhen Biotechnology; PRG-1801Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Pregene ShenZhen Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple myeloma
- Clinical Phase Unknown Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis
Most Recent Events
- 05 Feb 2024 Clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis (Treatment-resistant) in China (Parenteral) (NCT06277427)
- 05 Feb 2024 Clinical trials in Lupus nephritis (Treatment-resistant) in China (Parenteral) (NCT06277427)
- 06 Apr 2022 PRG 1801 licensed to CellPoint in Europe and USA